ACA Premiums Poised for Sharp Increase in 2026 Amid Federal Subsidy Cuts
ACA Marketplace premiums are set to rise sharply in 2026 due to federal subsidy cuts, risking coverage losses and market instability. Key states face increases up to 66%.
ACA Marketplace premiums are set to rise sharply in 2026 due to federal subsidy cuts, risking coverage losses and market instability. Key states face increases up to 66%.
Elevance Health lowers its 2025 profit outlook due to higher ACA and Medicaid costs driven by sicker patients and increased care utilization, reflecting an industry-wide trend. Analysts anticipate persistent insurer losses before improvement in 2026.
Explore how potential health insurance losses are affecting credit scores among low-income Americans and the resulting implications for insurance industry compliance and market strategies.
Colorado health insurers propose average 28.4% premium increases for 2025, driven by new state tax law impacts and market pressures. Western Slope sees hikes above 38%.
Explore how health insurance member portals equipped with personalized dashboards, self-service tools, and AI-driven communication enhance member engagement and support healthcare consumerism trends.
Curative Insurance Company retains AM Best A- rating for 3rd year, reflecting financial strength and innovative zero deductible employer health plans.
Mark Farrah Associates reports on profitability and performance metrics in the U.S. Individual and Small Group health insurance markets, based on NAIC data and trend analysis.
Congress must decide on extending ACA enhanced premium tax credits to prevent steep premium hikes and increased uninsured rates, with Florida particularly affected.
The U.S. Supreme Court upholds the ACA preventive services mandate, confirming employer group health plans must provide no-cost coverage for USPSTF-recommended services, maintaining regulatory compliance and stability.
Research reveals that survival disparities by insurance coverage have widened after immune checkpoint inhibitors approval for stage IV cancers, urging policy action to improve access and affordability.